Currently approved treatments provide only symptomatic relief or delay symptoms of Alzheimer’s disease and Parkinson’s disease at best. The tremendous unmet medical need demands effective disease modifying therapy combined with a diagnostic biomarker for the early detection of “preclinical or asymptomatic” stages of disease, thereby enabling the halting of disease or reversal of progression.
Learn More

Aestas Pharma Inc. is dedicated to the development of novel diagnostic imaging and therapeutic agents to enable the EARLY detection and REVERSAL of severely debilitating Alzheimer’s diseases (AD) and Parkinson’s disease (PD). In marked contrast to competitor approaches, including development stage diagnostic agents and drugs, Aestas is focused on targeting the very earliest stages of AD and PD, when clinical signs are not yet pronounced.
Learn More